This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by COSMAN, F. Articles by LINDSAY, R. Search for Related Content PubMed PubMed Citation Articles by COSMAN, F. Articles by LINDSAY, R.

Parathyroid Hormone-(1-34) [PTH-(l-34)]: Demonstration of Suppression of Endogenous Secretion Using Immunoradiometric Intact PTH-(l-84) Assay^*

Regional Bone Center, Helen Hayes Hospital West Haver straw, New York 10993
Department of Medicine, Columbia University College of Physicians and Surgeons New York, New York 10032

Address requests for reprints to: Dr. F. Cosman, Regional Bone Center, Helen Hayes Hospital, Route 9W, West Haverstraw, New York 10993.

Alterations in the sensitivity of the parathyroid gland to both stimulative and suppressive stimuli may be partially responsible for skeletal changes that occur with age, estrogen deficiency, osteoporosis, and estrogen treatment of osteoporosis. We sought to define the changes in intact PTH-(l–84) secretion in normal premenopausal and postmenopausal, osteoporotic and estrogen-treated osteoporotic women during the infusion of human (h) PTH-(l–34). hPTH-(l–34) was infused at 0.55 U/kg.h for 24 h, with serum sampling every 4 h. Serum was analyzed for calcium (ionized and total), hPTH-(l–34), and PTH-(l–84). Basal chemistries were no different among groups, except for serum phosphorus, which was highest in osteoporotic women (1.31 vs. 1.07 mmol/L in premenopausal; P < 0.02), and hPTH-(l–34), which was slightly higher in normal postmenopausal women (19.31 vs. 13.24 ng/L in estrogen treated; P < 0.02). No differences in PTH-(l–84) were found among groups. hPTH-(l–34) rose similarly in all patient groups, while the calcemic response was somewhat more sluggish in estrogentreated women, although statistically significant differences were not found. PTH-(l–84) declined rapidly in all patient groups, although estrogen-treated women had a smaller maximal decrease in PTH-(l–84), and the slope of the decremental change in PTH-(l–84) was lower in estrogen-treated women than in osteoporotic or normal postmenopausal women. Untreated osteoporotic women had less suppression of PTH-(l–84) than normal postmenopausal women at every calcium level. Estrogen treatment decreases the calcemic effects of infused hPTH-(l– 34) and at the same time reduces calcium-induced suppression of parathyroid secretion. It is possible that such changes in the set-point of the gland contribute to the alterations in bone turnover that result in osteoporosis and the mechanisms by which estrogen prevents bone loss.

^* This work was supported in part by NIH Grant AR-39191.

Received March 28, 1991.

This article has been cited by other articles:

				A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415. [Abstract] [Full Text] [PDF]

				A Iida-Klein, S S. Lu, R Kapadia, M Burkhart, A Moreno, D W Dempster, and R Lindsay Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice J. Endocrinol., September 1, 2005; 186(3): 549 - 557. [Abstract] [Full Text] [PDF]

				S. P Shrader and K. R Ragucci Parathyroid Hormone (1-84) and Treatment of Osteoporosis Ann. Pharmacother., September 1, 2005; 39(9): 1511 - 1516. [Abstract] [Full Text] [PDF]

				A. M. Ahmad, M. T. Hopkins, J. Thomas, B. H. Durham, W. D. Fraser, and J. P. Vora Parathyroid responsiveness to hypocalcemic and hypercalcemic stimuli in adult growth hormone deficiency after growth hormone replacement Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E986 - E993. [Abstract] [Full Text] [PDF]

				R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF]

				A. J. FELSENFELD and M. RODRIGUEZ Phosphorus, Regulation of Plasma Calcium, and Secondary Hyperparathyroidism: A Hypothesis to Integrate a Historical and ModernPerspective J. Am. Soc. Nephrol., April 1, 1999; 10(4): 878 - 890. [Full Text]

				H. Plotkin, C. Gundberg, M. Mitnick, and A. F. Stewart Dissociation of Bone Formation from Resorption during 2-Week Treatment with Human Parathyroid Hormone-Related Peptide-(1-36) in Humans: Potential as an Anabolic Therapy for Osteoporosis J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2786 - 2791. [Abstract] [Full Text]

				A. Toromanoff, P. Ammann, L. Mosekilde, J. S. Thomsen, and J.-L. Riond Parathyroid Hormone Increases Bone Formation and Improves Mineral Balance in Vitamin D-Deficient Female Rats Endocrinology, June 1, 1997; 138(6): 2449 - 2457. [Abstract] [Full Text] [PDF]